Welcome to our dedicated page for Sanara Medtech SEC filings (Ticker: SMTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sanara MedTech Inc. filings document a Nasdaq-listed medical technology company focused on surgical products for wound care, wound irrigation and bone fusion. Current Reports on Form 8-K record quarterly and annual results, preliminary financial information, investor presentations, strategic priorities, material-event disclosures and exhibits tied to press releases.
Proxy materials cover annual meeting matters, board and governance disclosures, executive compensation and shareholder voting. The filing record also includes disclosure categories for material agreements, capital structure, operating results and business realignment, including discontinued operations treatment for Tissue Health Plus.
Salamone Ann Beal reported acquisition or exercise transactions in this Form 4 filing.
Sanara MedTech Inc. director Ann Beal Salamone received a grant of 4,154 shares of restricted common stock as compensation under the company’s 2024 Omnibus Long-Term Incentive Plan. Following this award, she directly holds 26,858 shares of Sanara MedTech common stock.
The restricted stock will vest on the earlier of the company’s 2027 annual shareholder meeting or June 4, 2027, as long as she continues providing certain services to Sanara MedTech through that date.
Ortwein Sara N reported acquisition or exercise transactions in this Form 4 filing.
Sanara MedTech Inc. director Sara N. Ortwein received a grant of 4,616 shares of common stock as restricted stock under the company’s 2024 Omnibus Long-Term Incentive Plan. These shares were awarded at no cash cost and increase her direct holdings to 25,415 shares.
The restricted stock will vest on the earlier of the company’s 2027 annual shareholder meeting or June 4, 2027, as long as she continues providing specified services to Sanara MedTech through that date. This filing reflects a compensation-related equity award rather than an open-market share purchase or sale.
Mack Roszell III reported acquisition or exercise transactions in this Form 4 filing.
Sanara MedTech Inc. director Mack Roszell III received a grant of 5,308 shares of restricted common stock as equity compensation. The award was made at no cash price and increases his direct holdings to 21,842 shares.
The restricted stock will vest on the earlier of the company’s 2027 annual shareholder meeting or June 4, 2027, as long as he continues providing certain services to Sanara MedTech Inc. through that date. The grant was issued under the company’s 2024 Omnibus Long-Term Incentive Plan.
TANZBERGER ERIC D reported acquisition or exercise transactions in this Form 4 filing.
Sanara MedTech Inc. director Eric D. Tanzberger received a grant of 5,308 shares of common stock as restricted stock compensation, at a price of $0.00 per share. After this award, he directly holds 22,966 shares of Sanara MedTech common stock.
The restricted stock was granted under the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan and will vest on the earlier of the 2027 annual shareholder meeting or June 4, 2027, provided he continues to provide certain services to the company through that date.
Nixon Ronald T reported acquisition or exercise transactions in this Form 4 filing.
Sanara MedTech Inc. director and 10% owner Ronald T. Nixon received a grant of 4,154 shares of restricted common stock as equity compensation. The award was issued under the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan at no cash cost to him.
The restricted stock will vest on the earlier of the company’s 2027 annual shareholder meeting or June 4, 2027, if he continues providing certain services to the company through that date. Following this grant, he holds 68,196 shares of common stock directly.
In addition, separate from his direct holdings, 963,856 shares are owned of record by CGI Cellerate RX, LLC and 2,452,731 shares are owned of record by FA Sanara, LLC. These entities may share voting and dispositive control with Mr. Nixon and related entities, who disclaim beneficial ownership of those shares except to the extent of their pecuniary interests.
DeSutter Robert Andrew reported acquisition or exercise transactions in this Form 4 filing.
Sanara MedTech Inc. director Robert Andrew DeSutter reported receiving a grant of 5,539 shares of common stock as restricted stock, with no cash price per share. This is a compensation-related award, not an open-market purchase.
According to the filing, the restricted stock was granted under the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan and will vest on the earlier of the 2027 annual shareholder meeting or June 4, 2027, as long as DeSutter continues providing specified services to the company. After this grant, he directly holds 28,740 shares of Sanara MedTech common stock.
Major Eric D reported acquisition or exercise transactions in this Form 4 filing.
Sanara MedTech Inc. reported that director Eric D. Major received a grant of 4,846 shares of common stock as restricted stock under the company’s 2024 Omnibus Long-Term Incentive Plan. The grant was made at no cash cost to him and increases his direct holdings to 14,232 shares.
The restricted stock will vest on the earlier of the company’s 2027 annual shareholder meeting or June 4, 2027, as long as Major continues providing certain services to Sanara MedTech through that date. Until vesting, the award functions as equity-based compensation tied to his ongoing service to the company.
Myers Keith G reported acquisition or exercise transactions in this Form 4 filing.
Sanara MedTech Inc. director Keith G. Myers reported receiving a grant of 4,385 shares of common stock as restricted stock under the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan. The award was made at no cash cost per share and increases his directly held position to 9,325 shares.
The restricted stock will vest on the earlier of the company’s 2027 annual shareholder meeting or June 4, 2027, provided Myers continues to provide certain services to the company through that date.
Sanara MedTech Inc. has terminated its Transaction Advisory Services Agreement with The Catalyst Group, Inc., effective immediately on June 2, 2026. The move is tied to a strategic shift toward soft tissue repair and bone fusion products for the surgical market.
The agreement, originally effective March 1, 2023, had engaged Catalyst for transaction and strategic advisory services. Catalyst is affiliated with the Company’s chairman and, with its affiliates, beneficially owns more than 5% of Sanara’s common stock. No fee or penalty was paid for the termination, and covenants on indemnification and confidentiality remain in force.
Sanara MedTech Inc. Chief Executive Officer Yon Seth D reported an automatic share withholding related to equity compensation. On the vesting of 13,466 shares of restricted stock, 3,852 shares of common stock were withheld by the company to satisfy tax withholding obligations, based on a value of $21.06 per share. No shares were issued or sold in this transaction, and following the withholding, the CEO directly holds 109,546 shares of common stock.